de Souza M H, Abdelhay E, Silva M L, Diamond H R, Valente A N, Tabak D G, Bouzas L F, Ribeiro R C
Centro National de Transplante de Medula Ossea, Instituto Nacional do Cancer, Rio de Janeiro, Brazil.
Bone Marrow Transplant. 1992 Jun;9(6):495-7.
We describe a case of allograft rejection that occurred 23 months after successful bone marrow transplantation for severe aplastic anemia in a patient with paroxysmal nocturnal hemoglobinuria. The allograft rejection appears to have been induced by recombinant alpha-interferon (rINF-alpha) treatment for non-A, non-B hepatitis that developed 11 months after transplantation. During the 9 months of active hepatitis, the donor graft functioned normally; however, 3 months after rINF-alpha therapy was started, pancytopenia and a chimeric hematopoietic state developed. rINF-alpha was discontinued, cyclosporin A was reintroduced, and autologous bone marrow recovery followed. rINF-alpha treatment may be detrimental to some recipients of allogeneic bone marrow transplants.